Comparative Pharmacology
Head-to-head clinical analysis: METHOCARBAMOL AND ASPIRIN versus TRANCOPAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOCARBAMOL AND ASPIRIN versus TRANCOPAL.
METHOCARBAMOL AND ASPIRIN vs TRANCOPAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is unknown but may involve general CNS depression. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Trancopal (chlormezanone) is a centrally acting muscle relaxant and anxiolytic. Its exact mechanism is not fully understood, but it is believed to act on the central nervous system by depressing polysynaptic reflexes and possibly through GABAergic modulation.
1 to 2 tablets (methocarbamol 400 mg / aspirin 325 mg per tablet) orally every 4-6 hours as needed, not to exceed 6 tablets per day.
200-400 mg orally every 6 hours as needed for acute musculoskeletal pain; maximum 1.6 g per day.
None Documented
None Documented
Methocarbamol: 1–2 hours (terminal). Aspirin: 15–20 minutes for parent drug; salicylic acid: 2–3 hours (low doses) to 15–30 hours (high doses, due to saturable metabolism). Combined product: consider aspirin's longer terminal half-life at therapeutic doses.
Terminal elimination half-life: 20-30 hours in healthy adults. Prolonged in hepatic impairment (up to 60 hours).
Methocarbamol: Renal excretion of glucuronide and sulfate conjugates (95%) with <5% unchanged. Aspirin: Renal excretion of salicylic acid and metabolites (primarily salicyluric acid and glucuronides) with ~50% as salicylate at alkaline pH; biliary elimination <5%.
Primarily renal: ~95% as metabolites (glucuronides, sulfate conjugates) with <1% unchanged. Fecal: <5%.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant